Aclaris Therapeutics (ACRS) grants CSO 95,700 RSUs and 334,900 options

Rhea-AI Filing Summary

Aclaris Therapeutics reported an equity compensation grant to its Chief Scientific Officer, Roland Wilhelm Kolbeck, effective February 2, 2026. He received 95,700 restricted stock units, each representing one share of common stock, and an option to purchase 334,900 shares of common stock at an exercise price of $3.61 per share.

The restricted stock units vest in four equal installments on the first through fourth anniversaries of February 2, 2026, conditioned on his continued service. The stock option becomes exercisable as to 25% of the shares on each of the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continuous service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kolbeck Roland Wilhelm

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	95,700	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	334,900	$0.00	--

Holdings After Transaction: Restricted Stock Units — 95,700 shares (Direct); Employee Stock Option (Right to Buy) — 334,900 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kolbeck Roland Wilhelm

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/02/2026		A		95,700		(2)	(2)	Common Stock	95,700	$0	95,700	D
Employee Stock Option (Right to Buy)	$3.61	02/02/2026		A		334,900		(3)	02/01/2036	Common Stock	334,900	$0	334,900	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

3. Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Aclaris Therapeutics (ACRS) report for February 2, 2026?

Aclaris Therapeutics reported equity grants to Chief Scientific Officer Roland Wilhelm Kolbeck on February 2, 2026. He received 95,700 restricted stock units and an option for 334,900 shares of common stock as part of his compensation package.

How many restricted stock units were granted to the Aclaris (ACRS) Chief Scientific Officer?

The Chief Scientific Officer, Roland Wilhelm Kolbeck, was granted 95,700 restricted stock units. Each unit represents a contingent right to receive one share of Aclaris Therapeutics common stock, subject to time-based vesting and continued service requirements under the company’s equity plan.

What are the terms of the stock options granted to the Aclaris (ACRS) Chief Scientific Officer?

Roland Wilhelm Kolbeck received an employee stock option covering 334,900 shares of common stock at a $3.61 exercise price. The option vests in four equal annual installments, with 25% vesting on each anniversary of February 2, 2026, contingent on continuous service.

How do the Aclaris (ACRS) restricted stock units vest for the Chief Scientific Officer?

The 95,700 restricted stock units vest in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026. Vesting is conditioned on the Chief Scientific Officer’s continuous service as defined in the company’s equity incentive plan.

Is the Aclaris (ACRS) Form 4 transaction a purchase or a grant?

The Form 4 reports equity compensation grants, not open-market purchases. It shows the Chief Scientific Officer acquiring restricted stock units and stock options at a reported acquisition price of $0, with the options exercisable at a $3.61 per share exercise price.

What role does Roland Wilhelm Kolbeck hold at Aclaris Therapeutics (ACRS)?

Roland Wilhelm Kolbeck is identified as the Chief Scientific Officer of Aclaris Therapeutics. The Form 4 indicates he is an officer of the company, rather than a director or 10% owner, and discloses equity awards tied to his executive role and continued service.